Vivanta 97 mg+103 mg (Tablet)
Unit Price: ৳ 120.00 (1 x 10: ৳ 1,200.00)
Strip Price: ৳ 1,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Beximco pharmaceuticals ltd |
| Also available as |
Title
- Heart Failure Medication
Categories
- Medicine
- Healthcare
- Cardiology
Description
- This medication is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction. It is also used for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
DosageRange
24/26 mg to 97/103 mg twice daily
Pharmacology
- Contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. It inhibits neprilysin via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 receptor via valsartan. The cardiovascular and renal effects in heart failure patients are attributed to the increased levels of peptides degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan.
Interaction
- Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided. Potassium-sparing diuretics may increase serum potassium levels. Risk of renal impairment may be increased with NSAIDs. Increased risk of lithium toxicity with lithium.
Contraindications
- In patients with hypersensitivity to any component. In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy. Should not administer within 36 hours of switching from or to an ACE inhibitor. Contraindicated with concomitant use of aliskiren in patients with diabetes.
SideEffects
- Angioedema
- Hypotension
- Impaired Renal Function
- Hyperkalemia
- Cough
- Dizziness
PregnancyAndLactation
- Safety and effectiveness have not been established in pediatric patients less than 1 year of age. No relevant pharmacokinetic differences in elderly or very elderly patients. No dose adjustment required in patients with mild hepatic impairment. Not recommended in patients with severe hepatic impairment. No dose adjustment required in patients with mild to moderate renal impairment.
PrecautionsAndWarnings
- May cause angioedema and must not be used in patients with a known history of angioedema related to previous ACE inhibitor or ARB therapy and in patients with hereditary angioedema. Lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine and down-titrate or interrupt in patients who develop a clinically significant decrease in renal function. Monitor serum potassium periodically and treat appropriately.
SpecialPopulationUse
- Safety and effectiveness not established in pediatric patients. No relevant pharmacokinetic differences in elderly patients. Starting dose adjustment recommended for patients with severe renal or hepatic impairment.
OverdoseEffects
- Hypotension is the most likely result of overdosage. Symptomatic treatment should be provided. Unlikely to be removed by hemodialysis due to high protein binding.
StorageConditions
- Keep in a dry place below 30°C. Protect from moisture and keep out of the reach of children.
UsabilityFeatures
- Oral medication
- Treats chronic heart failure
- Suitable for pediatric patients aged one year and older
TechnicalSpecifications
- Neprilysin inhibitor
- Angiotensin receptor blocker
- Available in doses ranging from 24/26 mg to 97/103 mg
DesignElements
- Tablet form
ColorOptions
- No specific color options
Materials
- Active ingredients: sacubitril, valsartan
Dimensions
- Standard tablet size
Function
- Reduces the risk of cardiovascular death and hospitalization for heart failure
- Treats symptomatic heart failure with left ventricular dysfunction
- Increases peptide levels degraded by neprilysin
Compatibility
- Not to be used with ACE inhibitors, aliskiren, or potassium-sparing diuretics
SafetyFeatures
- Closely monitor for angioedema, hypotension, impaired renal function, and hyperkalemia
DosingInstructions
- Starting dose: 24/26 mg twice daily. Target maintenance dose: 97/103 mg twice daily